Similar articles

• Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  Chamberlain MC. Chamberlain MC. Neurology. 2009 Feb 24;72(8):772-3; author reply 773-4. doi: 10.1212/01.wnl.0000339387.03225.0a. Neurology. 2009. PMID: 19237713 No abstract available.
• Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  Mrugala MM. Mrugala MM. Neurology. 2009 Feb 24;72(8):773; author reply 773-4. Neurology. 2009. PMID: 19248218 No abstract available.
• Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Norden AD, et al. Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38. Neurology. 2008. PMID: 18316689
• Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.

  Chamberlain MC. Chamberlain MC. Cancer. 2010 Sep 1;116(17):3988-99. doi: 10.1002/cncr.25256. Cancer. 2010. PMID: 20564141 Review.
• Bevacizumab for the treatment of high-grade glioma.

  Khasraw M, Simeonovic M, Grommes C. Khasraw M, et al. Expert Opin Biol Ther. 2012 Aug;12(8):1101-11. doi: 10.1517/14712598.2012.694422. Epub 2012 Jun 5. Expert Opin Biol Ther. 2012. PMID: 22663137 Review.